We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized ...

Individuals with ulcerative colitis have an increased risk for certain types of cancer based on age, instead of treatment type.

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years with plaque psoriasis or ...

Compared with adalimumab, several biologic medications had superior safety profiles for the treatment of moderate to severe psoriasis.

Expanding access to advanced therapies while making healthcare more affordable is central to our mission, said Mitchell ...

“The positive results from this confirmatory patient study represent an important step in the development of the Xolair® biosimilar candidate. We look forward to working with our partners to increase ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and ...

CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing USYMRO® to the reference product ...

INCHEON, South Korea, June 16, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab-stba), a ...